Grifols, S.A. (GIFLF)
| Previous Close | 14.30 |
| Open | 14.30 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 14.30 - 14.30 |
| 52 Week Range | 14.01 - 25.91 |
| Volume | |
| Avg. Volume | 1,845 |
| Market Cap | 6.037B |
| Beta (5Y Monthly) | 0.14 |
| PE Ratio (TTM) | 143.00 |
| EPS (TTM) | 0.10 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 03, 2021 |
| 1y Target Est | N/A |
- Reuters
Grifols not currently planning capital increase - source
BARCELONA (Reuters) -Spanish pharmaceuticals company Grifols has no current plans for a capital increase, a company executive told investors on Thursday in response to a news report, a source with knowledge of the matter said. The source said Grifols vice president Nuria Pascual read a statement on behalf of Grifols' chairman, Victor Grifols Roura at an investor day on Thursday, which said: "Regarding the unexpected news published yesterday in Spanish media and replicated by the financial press we want to inform that, for the time being, the board is not analysing any increase in share capital."
- Reuters
Grifols' shares fall 6% on media report of possible capital increase
Shares of Spanish pharmaceuticals company Grifols were down 6% on Wednesday morning after news website El Confidencial reported the company was considering a 2 billion euro ($2.10 billion) capital increase to reduce its debt. Quoting unidentified market sources, the news outlet reported that Grifols, which specialises in blood plasma-based drugs, was negotiating with several funds over a capital increase equivalent to almost 20% of the company valuation. A spokesperson at Grifols said the company would not comment on market rumours.
- Motley Fool
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond
On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.
